Conception

Executive Summary

Conception is a private biotechnology company based in San Diego, California, founded in 2018. The company is pioneering in-vitro gametogenesis (IVG) technology, which aims to produce functional human eggs from induced pluripotent stem cells (iPSCs). By combining stem cell biology, tissue engineering, and computational methods, Conception seeks to address a wide range of fertility challenges, including age-related infertility, genetic disorders, and same-sex reproduction. The platform holds the potential to revolutionize reproductive medicine by enabling the creation of eggs from any individual, effectively eliminating biological limits on fertility. Conception's approach is highly innovative but remains at an early stage, with no disclosed funding rounds or clinical trials to date. The company's progress depends on overcoming significant scientific hurdles, such as ensuring genomic stability and proper epigenetic reprogramming of derived gametes. If successful, Conception could unlock a multi-billion dollar market in fertility treatments and genetic disease prevention, though technical and regulatory challenges remain substantial.

Upcoming Catalysts (preview)

• 2026-2027Publication of non-human primate proof-of-concept data60% success
• 2026-2027Series A funding round closing70% success
• 2027-2028Pre-IND meeting with FDA to discuss development pathway50% success